Our immune system protects us from all kinds of pathogens our body faces every day.
Introduction
The immune system protects the human body from all kinds of pathogens. The importance of our immune system for health is dramatically illustrated by the frequent observation that individuals with defective immune responses are susceptible to serious, often lifethreatening infections. Conversely, abnormal immune responses can cause autoimmune diseases, with serious morbidity and mortality (1) . Autoimmune diseases are a range of diseases, in which the immune response to self-antigens results in damage or dysfunction of tissues. Autoimmune diseases can be systemic or can affect specific organs or body systems (2) . Autoantibodies are mainly produced by B cells. When naïve B cells (CD22+ cells) are activated by antigen, they proliferate and differentiate into effector cells, also called plasma cells. These effector cells produce and secrete antibodies (1, 3) . These antibodies, also called immunoglobulins exist of two heavy and two light chains. There are different subtypes of heavy chains, like: IgG, IgM and IgA. The light chain belong either to the kappa or lambda type (1) . The human antibody response exists of two phases. The first response is the primary antibody response, in which predominantly immunoglobulin M (IgM) is produced. In the secondary antibody response there is an antibody switch to the IgG isotype, which is called heavy chain isotype switching.
Myasthenia gravis (MG) is a rare autoimmune disease characterized by the production of autoantibodies against proteins of the postsynaptic membrane in the neuromuscular junction (NMJ). This leads to weakness and fatigability of skeletal and extra-ocular muscles (4) . Three subclasses of myasthenia gravis are identified. Patients with the "MuSK-MG" form are of importance in this study. These patients process antibodies against the muscle-specific tyrosine kinase (MuSK) (4) (5) (6) . MuSK is a postsynaptic neuromuscular protein involved in acetylcholine receptor (AChR) clustering (7) (8) (9) , which is important for the communication between nerve and muscle. These antibodies belong predominantly to the IgG4 subclass and are not associated with damage to the neuromuscular junction (4) . However, also IgG1 can be produced by these patients (10) .
The main effect of MuSK antibodies at the neuromuscular junction is still unclear. MuSK antibodies may not only inhibit MuSK function directly, but also increase the turnover of MuSK, thereby further reducing its activity (9) . These findings suggest that MuSK-MG may be different in etiological and pathological mechanisms, compared to AChR-MG, in which patients produce autoantibodies against the AChR. In MuSK-MG, the postsynaptic machinery becomes structurally and functionally disorganized by a significant reduction in AChR clustering (7, 9) . MuSK-MG is an early-onset myasthenia gravis (EOMG) that occurs predominantly in middle-aged woman, and is often severe (7, 8, 10) . The risk of myasthenic crisis is particularly high, and the chances of achieving complete stable 308 remission are significantly lower than in AChR-MG (10) .Current treatments are steroid and immunosuppressive drugs for patients with MuSK-MG (5).
This paper is about a project on MuSK-MG with a pathologic approach, in which MuSK-MG patients' antibodies are investigated. The aim of this study was to sequence and generate antibodies of MuSK-MG patients in vitro to gain more insight into the pathological mechanisms of this form of myasthenia gravis and to test new drugs without the use of patients or patients' blood in future. The hypothesis is that the immortalized B cell clones will produce IgG4 or IgG1 antibodies against MuSK. To achieve this, B cells were isolated from MuSK-MG patients' blood, cultured, and immortalized with the Epstein Barr virus (EBV). After immortalization, B cell clones were stimulated to grow and produce antibodies. The supernatants of the B cell clones were screened for antibody production against MuSK. From positive B cell clones RNA was extracted, converted to DNA, and inserted in an immunoglobulin vector, which will be transfected in a HEK-cell line. With this method, MuSK-MG patient antibody producing cells will be obtained.
Material and methods

Patients
The exact characteristics of the five patients, from which blood was taken, are unknown.
The only characteristic known was that the patients were classified as MuSK-MG patients and that they were from Leiden and Maastricht University. In general, MuSK-MG has an early onset of disease, occurs predominantly in middle-aged woman and is often severe (7, 8, 10) .
Isolation of human B cells
The cell fraction of peripheral mononuclear blood cells (PMBCs), including B cells, was isolated from whole MuSK-MG patient blood by Density Gradient Centrifugation using 
RNA extraction and immunoglobulin gene amplification
From MuSK antibody, either IgG or IgM, producing B cell clones, RNA was extracted to obtain the immunoglobulin (antibody) genes. After RNA extraction, first-strand cDNA synthesis was performed. In this first-strand cDNA synthesis a small single stranded DNA (primer) binds to the single stranded RNA. In presence of a reverse transcriptase, which is an enzyme that can elongate from the primer on, the primer was elongated. After elongation an RNAse was added, which leads to the degradation of the RNA strand. The result of this procedure was a single stranded cDNA. After first-strand cDNA synthesis, cDNA was stored at -80°C or directly used for amplification by polymerase chain reaction (PCR). Different primers were used to amplify the immunoglobulin DNA fragments. In this PCRs a difference was made in heavy and light chain gene amplifications. After the amplification by PCR, obtained immunoglobulin genes were analyzed by agarose (UltrapureTM Agarose, Invitrogen) gel electrophoresis and visualized by ethidium bromide staining. In this gel elektrophoresis, gene fragments run in the gel dependent of their length in base paires. A 100 Base-Pair (bp) ladder (Invitrogen) was used, as the heavy chain products were around 400 bp (12) and the light chain products were around 300 bp (13) in length. When the immunoglobulin genes were visualized in the gels, amplification products were purified to obtain a pure solution of amplified immunoglobulin genes. 
Sequencing
Sequencing is a method to obtain the genetic code of DNA. To obtain the sequence of the purified immunoglobulin genes of the immortalized B cell clones, the Sanger sequencing method was used, which is based on the selective incorporation of chain-terminationg dideoxynucleotides, which are the building blocks of DNA.The sequence reactions were purified by use of MicrospinTM G50 Columns (GE Healthcare). The purified sequencing reactions were added to a 0.1 ml reaction plate (MicroAMP® Optical 96-well, Applied Biosystems). Sequences were analysed by the genetic analyser ABI300 (Applied Biosystems) and Chromas Lite (Version 2.1.1).
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Transfection of immunoglobulin genes in human embryonic kidney (HEK)-cell line
To transfect the immunoglobulin genes obtained from MuSK-MG patients blood, these genes had first to be placed in vectors. A vector is a circular double stranded DNA that can ligate a DNA fragment and has a antibiotic resistance to make sure that only bacteria that toke up the vector will grow on petridishes that contain this specific antibiotic. The ligation products will be extracted from the bacteria and these products will be placed, also called transfected, in a human embryonic kidney (HEK) cell-line. With this method antibodies produced by MuSK-MG patients will be produced by these cells in vitro.
Results
Immortalized B cell clones produce IgG and IgM against MuSK
Antibody production screening resulted in immortalized B cell clones with activity against which were screened every week after stimulation, showed striking differences in antibody production.
Ten immunoglobulin genes were extracted for sequencing and transfection
From 10 immortalized B cell clones, which were repeatedly positive in the ELISA screening, RNA was extracted (table 1) . From the first patient RNA was extracted from 2 B cell clones.
From the G41 B cell clone IgG λ genes were extracted. From the F42 B cell clone IgM κ genes were extracted. From the second patient IgG λ genes were extracted from B cell clone F62.
From the third patient no immunoglobulin genes were extracted as these clones did not show growing and high antibody production in the screening. From the fourth patient IgM κ genes were extracted from B cell clone C61. From the fifth patient 6 IgM heavy chain genes were extracted. From five of these clones λ genes were extracted. From one of these clones both κ and λ genes were extracted. 
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( figure 2) . However, the sequences were not complete. The first and last part, around 100 base pairs (bp), of the sequences were missing. 
Restrictions of the vectors and obtained immunoglobulin genes were complete
All four vectors were digested by two restriction enzymes. The IgG1 and IgG4 vectors were digested by the restriction enzymes EcoRI and NheI ( figure 3 ). The control reaction
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(C), without enzyme, showed two bands for the IgG1 and IgG4 vector, which showed the uncut, circular formations of the vector. However, the intensity of the bands of the IgG4 control reaction was very low. The EcoRI digestion was absent in both IgG1 and IgG4 vectors, as two bands appeared at the same level as the control reaction without enzyme (C), which showed that this restriction enzyme was not digesting the vector. However, after increasing reaction volume and incubation time and decreasing the amount of DNA, the digestions by EcoRI were complete. The NheI digestion was almost complete for the IgG1 vector and complete for the IgG4 vector, as it showed one band, which appeared higher in the gel than the lower band of the control, which indicate that the vector linearized (dashed square), and thereby cut. 
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antibodies with reactivity against MuSK. From these antibodies the majority belonged to the IgM isotype. Moreover, this screening showed that the sorting by FACS went well, as all CD22+MuSK+IgG-sorted B cells were negative for IgG. Furthermore, the subsequent supernatants, which were screened every week after stimulation, showed striking differences in antibody production. This may be due to the fact that taken off the supernatants may have damaged the cells, which leads to a decreased antibody production in the following screening week.
From ten B cell clones that produced antibodies against MuSK, RNA was extracted and the immunoglobulin genes, both heavy and light chains, were amplified. This resulted in 2
IgG λ genes, 2 IgM κ genes and 6 IgM λ genes, from which one showed also amplifications for the kappa light chain. The gene amplifications confirmed that the majority of the produced antibodies against MuSK belonged to the IgM isotype, with a predominance of lambda light chains. It was expected that the produced antibodies by the immortalized B cell clones would predominantly belong to the IgG4 isotype as described in literature (5, 9, 14) . However, the majority of the immortalized B cell clones showed to produce IgM antibodies against MuSK. Moreover, there was a predominance of lambda light chains, which is striking as normally 60-75% of the light chains belong to the kappa type (15, 16) .
Sequencing of the obtained immunoglobulin genes showed incomplete sequences.
According to literature, human heavy chains are around 400 bp in length (12) and light chains are around 300 bp in length (13) . The obtained sequences of the heavy chains were missing around 100 bp. Furthermore, nucleotide peaks were low and often peaks of different nucleotides had the same height, which made it hard to obtain the correct sequence. At the moment, we are trying to improve our sequencing results. Moreover, ligation products will be sequenced and will be compared to the first, incomplete sequences.
Vector cloning went well, as all four vectors were cloned. However, the selection and growing of the vectors showed some differences in efficiency. This may be due to differences in vectors or bacteria used for transformation. From all four vectors, a high amount of pure, uncontaminated DNA was obtained. As a high amount of IgM amplifications were obtained, also an IgM vector will be used for cloning. The subsequent restrictions of the vectors showed incomplete restriction by EcoRI. However, after increasing the reaction volume and incubation time and decreasing the amount of DNA, the digestions by EcoRI were complete. As the restrictions of the vectors were complete, PCR products were restricted as well. These digested PCR products were ligated with the appropriate restricted vectors. The ligation products will be amplified in bacteria and the amplified ligation products will be transfected in a HEK cell line to generate antibodies produced by
MuSK-MG patients in vitro.
The limitations of this study were the low number of patients and also the small amount of blood used for the immortalization. This is only a small part of the whole mechanism, which makes it hard to make an overall conclusion on MuSK-MG. However, this study showed a predominance of IgM production against MuSK. This could mean that IgM plays an important role in the pathology of MuSK-MG, as was already suggested by Yamamoto et al in 1991 (17) and Hofstad et al in 1992 (18) . Both purposed that the heavy chain isotype switch from IgM to IgG was missing in seronegative patients and thereby these patients produce IgM for an indefinite time. However, MuSK-MG was not identified yet (2001) during these studies (10) . In 2003, IgM antibodies were again found in seronegative patients, but not in the MuSK-MG fraction (19) . Normally, these IgM autoantibodies are not found during established disease (20) . However, this study confirms that IgM may play an important role in the pathology of MuSK-MG. Moreover, it is confirmed that IgM is an very efficient activator of immune system, which indicates it importance in autoimmunity (18) .
The pathophysiology of IgM is rarely a focus in human autoimmune disease (20) . Therefore, 
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